Source: Syrian Arab News Agency (SANA), by Nawal Jeles (September 28, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- Sungkyunkwan University combined a human brainstem organoid, dopamine sensor, and microfluidic chip to monitor drug responses for 12 hours.
- The platform showed that increasing drug concentration did not necessarily create a stronger response in the tested neural model.
- The findings do not establish a Parkinson's drug dose for patients or clinical readiness of the platform.
Researchers at Sungkyunkwan University in South Korea have built a biochip that follows how laboratory-grown human neural tissue responds to Parkinson's drugs over time. The platform pairs a three-dimensional brainstem organoid with an optical sensor that detects dopamine, the chemical messenger depleted in Parkinson's disease. By continuously measuring dopamine release for 12 hours while delivering drugs through microscopic channels, the team could see when a response began, peaked, and faded. The work could give drug researchers a way to test candidate treatments in living human tissue models before moving toward clinical studies.
A brain tissue model with a built-in sensor
The device combines a brainstem organoid, a small laboratory-grown tissue model derived from human stem cells, with a nanoplasmonic optical sensor. Organoids do not reproduce an entire human organ, but they can mimic selected features of tissues that are difficult to study directly.
Here, the organoid provides neural tissue that can release dopamine. Parkinson's disease progressively damages dopamine-producing nerve cells, leading primarily to movement-related symptoms such as tremors, slower movement, stiffness, and problems with balance.
Detecting dopamine without damaging tissue
The sensor relies on an aptamer, an artificial DNA molecule designed to bind dopamine. It is attached to a structure containing gold nanoholes and an optical resonator, which detects changes in light when dopamine interacts with the sensing system.
A useful analogy is a microscopic listening device placed beside the tissue rather than a probe pushed into it. The approach allowed the researchers to measure dopamine released by the neural model without damaging the organoid during monitoring.
Microfluidic drug delivery
A microfluidic chip moves drugs and culture medium through tiny channels around the organoid. This setup let the Sungkyunkwan University teams, led by biophysics professors Kim In-ki and Park Jong-chan, expose the tissue to drugs while recording its biochemical response continuously.
During 12-hour tests, the platform captured the timing of each response, including its onset, peak, and decline. That time-resolved view matters because a single measurement could miss whether a drug acts quickly, slowly, or only briefly.
Drug concentration did not follow a simple pattern
The experiments found that raising drug concentration did not necessarily produce a stronger dopamine-related response in the neural model. Instead, the researchers identified a concentration that performed best under the tested conditions.
That result should not be read as a patient dosing recommendation. It reflects performance in a laboratory-grown tissue system, not safety, effectiveness, or an appropriate dose in people with Parkinson's disease.
Why This Matters
Drug development needs models that are closer to human biology than conventional cell cultures while remaining practical for repeated experiments. By joining an organoid, a dopamine sensor, and controlled fluid delivery on one platform, the device is designed to reveal changing drug effects in real time rather than only at an experiment's endpoint.
Kim said the system could support longer-term studies of drug responses in living human tissue and may eventually be developed for research on patient-specific treatments. Further work will be needed before the platform can be used in clinical settings, but it offers a focused way to investigate prospective Parkinson's therapies in a human neural model.
Topics: Biochip · Microfluidics · Brain & neurological health
Start here: What is a biochip?